Deerfield Management Company, L.P. (Series C) Harpoon Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

  • $5.38 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 14, 2020
SELL
$11.11 - $24.72 $1.86 Million - $4.14 Million
-167,637 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$10.74 - $16.32 $1.8 Million - $2.74 Million
167,637 New
167,637 $1.94 Million
Q4 2019

Feb 14, 2020
SELL
$12.94 - $20.58 $3.42 Million - $5.44 Million
-264,497 Closed
0 $0
Q3 2019

Nov 14, 2019
SELL
$10.93 - $17.47 $224,097 - $358,187
-20,503 Reduced 7.19%
264,497 $3.61 Million
Q1 2019

May 15, 2019
BUY
$9.47 - $17.01 $2.7 Million - $4.85 Million
285,000 New
285,000 $2.7 Million

Others Institutions Holding HARP

# of Institutions
2
Shares Held
353K
Call Options Held
0
Put Options Held
0
View Full List

About Harpoon Therapeutics, Inc.

HARP Quotes by TradingView
  • Ticker HARP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,106,800
  • Description
  • Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...
More about HARP
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email